Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

98 results about "Dysbacterioses" patented technology

Bifidobacterium animalis subsp. Lactis, preparation and application of bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.
Owner:JILIN AGRICULTURAL UNIV

Application of probiotic composition in preparation of medicine for preventing and treating ulcerative colitis

The invention belongs to the field of microorganisms. The invention provides an application of a probiotic composition in preparation of medicines for preventing and treating ulcerative colitis, the probiotic composition comprises a combination of bacillus coagulans and clostridium butyricum, and the combination of bacillus coagulans and clostridium butyricum comprises a combination of bacillus coagulans and clostridium butyricum. The bacillus coagulans is bacillus coagulans JSSW-LA-07-1 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.10182, and the clostridium butyricum is clostridium butyricum JSIM-MCB20040312 with the preservation number of CGMCC No.1647. The bacillus coagulans and the clostridium butyricum are used for preparing the bacillus coagulans and the clostridium butyricum. The probiotic composition has the capacity of preventing and treating ulcerative colitis, the ulcerative colitis treating effect is better than that of positive control medicine salazosulfapyridine, the obvious ulcerative colitis treating effect is achieved, the inflammatory factor content and the oxidative stress level are remarkably reduced, inflammatory cell infiltration is reduced, intestinal flora imbalance is improved, and the effect of preventing and treating ulcerative colitis is achieved. Meanwhile, the effect of promoting planting of probiotics is achieved.
Owner:SHANGHAI FOURTH PEOPLES HOSPITAL

Application of bifidobacterium pseudolongum in preparation of composition for treating intestinal flora imbalance or intestinal inflammation

PendingCN118924796Aease intestinal inflammationDigestive systemUnknown materialsBiotechnologyDietary supplement
The invention discloses application of bifidobacterium pseudolongum in preparation of a composition for treating intestinal flora imbalance or intestinal inflammation, and relates to the technical field of microorganisms. According to the application of the bifidobacterium pseudolongum in preparation of the composition for treating the intestinal dysbacteriosis, the bifidobacterium pseudolongum is used for preparing the composition for treating the intestinal dysbacteriosis, and the composition comprises a fermented product, a bacterial powder preparation and a dietary supplement. The viable count in the bacterial powder preparation and the dietary supplement is 1.5 * 10 < 8 >-5 * 10 < 8 > CFU / g. According to the application of the bifidobacterium pseudolongum to preparation of the composition for treating the intestinal dysbacteriosis or the intestinal inflammation, the bifidobacterium pseudolongum can regulate the balance of the intestinal flora, relieve the pathological symptoms of the intestinal tract and relieve the intestinal inflammation, and can be widely used for preparing the composition for treating the intestinal dysbacteriosis or the intestinal inflammation.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Application of animal bifidobacterium subspecies F1-7 in preparation of medicine for preventing or treating sarcopenia

The invention discloses application of a bifidobacterium animalis subspecies F1-7 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-7 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of drugs for improving bile acid metabolic function decline caused by sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of a medicine for improving intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-7 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, regulate intestinal flora, promote bile acid metabolism and further relieve muscular atrophy, and enriches a probiotic library for improving sarcopenia.
Owner:OCEAN UNIV OF CHINA

Application of animal bifidobacterium subspecies F1-3-2 in preparation of medicine for preventing or treating sarcopenia

The invention discloses application of a bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-3-2 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for correcting intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-3-2 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, improve the level of serum markers in sarcopenia, regulate the homeostasis of intestinal flora so as to relieve muscular atrophy, prepare freeze-dried bacterial powder and enrich products for improving sarcopenia.
Owner:OCEAN UNIV OF CHINA

Application of feed additive for improving intestinal flora disorder of poultry in feed

PendingCN119073468AAlleviate disordersease intestinal inflammationFood processingAnimal feeding stuffBiotechnologyBacteroides
The invention discloses application of a feed additive for improving intestinal flora disorder of poultry in feed. According to the poultry feed, pyrroloquinoline quinone is added into the poultry feed, the poultry intestinal flora disorder can be relieved, the abundance of intestinal flora in poultry intestinal tracts can be adjusted, and the intestinal flora comprises at least one of bacteroides, proteobacteria, firmicobacteria, another mycobacterium, Escherichia-Shigella and Clostridium praeparatum. Pyrroloquinoline quinone is added into the feed, so that intestinal inflammation, intestinal injury and alteration of microbial flora in intestinal tracts caused by intake of microplastics of poultry can be relieved, the structure of the microbial flora in the intestinal tracts can be changed, and by adjusting the microbial flora in the intestinal tracts, the immunity of poultry can be improved. According to the present invention, the abundance of the BPA, namely bacteroides, proteobacteria, thick-wall bacteria, other mycobacterium, Escherichia-Shigella or Clostridium praeparatum, can be improved, such that the intestinal inflammation and the intestinal injury of the poultry can be relieved so as to improve the intestinal microorganism disorder of the poultry caused by the BPA.
Owner:JIANGSU INST OF POULTRY SCI

Post-combination prebiotic ferment powder and application thereof

The invention discloses combined prebiotic ferment powder and application thereof. The combined prebiotics ferment powder is a dried product obtained after the compound lactic acid bacteria composition is fermented; wherein the cell number ratio of each fermentation strain is as follows: LRH10 (12 + / -0.5%), LPC12 (2 + / -0.5%), LF26 (26.3 + / -0.5%), ST30 (21.6 + / -0.5%) and LH43 (38.1 + / -0.5%). According to the present invention, the combined probiotic fermentation powder has significant promotion effect on the growth of Bifidobacterium longum BL986, such that the combined probiotic fermentation powder can be used for preparing the drug for relieving the senile intestinal flora disorder.
Owner:SYNBIOTECH BIOTECHNOLOGY YANGZHOU CO LTD

Host DNA as a biomarker of vaginal health

The present invention relates to an in vitro method for diagnosing Bacterial Vaginosis (BV) in a subject comprising: a) obtaining a biological sample from said subject, b) analysing the relative abundance of the host DNA in said sample and c) diagnosing that said subject suffers from bacterial vaginosis if said relative abundance is lower than a reference value. The present invention also relates to an in vitro method for diagnosing the severity of the vaginal dysbiosis in a subject, comprising the steps of: a) obtaining a biological sample from said subject, b) analysing the relative abundance of the host DNA in said sample and c) diagnosing that said subject has a severe vaginal dysbiosis if said relative abundance is lower than another reference value.
Owner:LUXIA SCI

Probiotic composition for gut microbiome modulation

Preparations can be used for treating or preventing dysbiosis in humans and animals. The preparation has the probiotic strains Lactobacillus plantarum DSM 33363, Lactobacillus plantarum DSM 33364, Lactobacillus paracasei DSM 33373, Lactobacillus reuteri DSM 33374, Bacillus megaterium DSM 33300, Bacillus pumilus DSM 33297, and Bacillus pumilus DSM 33355. The preparation can be used for the modulation of the composition and activity of gut microbiota
Owner:EVONIK OPERATIONS GMBH

Nisin for inhibiting biofilms

The invention relates to a dental and / or oral care product comprising between 0.0039% and 0.0078% by weight of nisin establishing and / or maintaining a pH of at least 4.5 in situ. Although said rather low nisin concentration does not provide an anti-bacterial effect, it is surprisingly and advantageously capable of maintaining stable pH values of at least 4.5, thereby preventing destruction of a subject's teeth enamel based on enamel demineralization effects at pH below 4.5, and said low nisin concentration advantageously further avoids dysbacteriosis, i.e. the oral microflora remains balanced, thus not leading to an increase of e.g. periodontitis associated bacteria.
Owner:SKYLAB AG

Preparation method and application of multifunctional nanospheres targeting bacteria

The present invention is applicable to the field of biomedical technology, and provides a preparation method and application of multifunctional nanospheres targeting bacteria. The prepared targeted multifunctional nanospheres have both PDT / PTT functions and target harmful bacteria for antibacterial treatment of periodontitis. By using bismuth silver sulfide hollow nanospheres, photosensitizers and bacterial outer membrane vesicles as raw materials, the raw materials are cheap and the preparation process is simple. The prepared multifunctional nanospheres have unique advantages. They will not cause damage to probiotics, but can accurately target harmful bacteria and exert antibacterial effects, thereby effectively solving the problem of dysbacteriosis. In addition, the direct contact between the multifunctional nanospheres and bacteria will interfere with the electron transfer behavior of the bacteria, which is conducive to strengthening the bactericidal effect on bacteria. The adopted targeting strategy is extremely suitable for the treatment of dysbacteriosis diseases, showing a broad application prospect.
Owner:JILIN UNIVERSITY

Methods and compositions related to prebiotic formulations useful for promoting health of urogenital system

The prebiotic formulation is capable of modulating the growth and / or activity of microorganisms in a region of the urogenital system. Such prebiotic formulations can comprise isomaltulose and at least one other prebiotic, such as 1-kestose or lactulose. These modulated microorganisms can be directly related to the health of the urogenital system, and their modulation can be used to prevent, control or treat dysbacteriosis in the region of the urogenital system.
Owner:KIMBERLY CLARK WORLDWIDE INC

Long-term stabilization, formulation and tableting of live microbial cells

Provided herein are compositions comprising Escherichia coli (E. coli), Saccharomyces boulardii (S. boulardii), Lactobacillus plantarum (L. plantarum), and / or Ensifer meliloti (E. meliloti) and a first stabilizing excipient. Also provided herein are methods of delivering E. coli, S. boulardii, L. plantarum, and / or E. meliloti to a subject in need thereof, methods of inducing bacterial growth in a subject or in a cell, tissue, or biological sample, and methods of inhibiting an enteric pathogen in a subject or in a cell, tissue, or biological sample. Further provided herein are methods of treating dysbiosis in a subject in need thereof.
Owner:MASSACHUSETTS INST OF TECH +1

Managing microbial dysbiosis with temocillin

Provided herein are methods of using temocillin to control microbial dysbiosis arising from, in certain instances, enterobacteriacea overgrowth such as overgrowth from adherent invasive E. coli (AIEC). Methods of using temocillin to treat intestinal disorders and symptoms of such caused by microbial dysbiosis, as well as other disorders are contemplated herein.
Owner:ENTASIS THERAPEUTICS INC

Compositions for modulating gut microflora populations, treatment of dysbiosis and disease prevention, and methods for making and using same

PendingEP4673157A2Powder deliveryAntiviralsMicrobiota decussataGut microflora
In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, comprising combinations or formulations of microbes, such as non-pathogenic, live bacteria and / or bacterial spores, for example as probiotics, for the control, amelioration, prevention, and treatment of a disease or condition, for example, a dysbiosis, or for augmenting the health or ability to thrive in an individual. In alternative embodiments, provided are compositions or formulations, including products of manufacture and kits, and methods, comprising at least one non-pathogenic, live bacteria and / or bacterial spore and at least one probiotic, or synbiotic. In alternative embodiment, these non-pathogenic, live bacteria and / or bacterial spores (and optionally also a probiotic) are administered to an individual in need thereof, thereby resulting in a modification or modulation of the individual's gut microfloral population(s).
Owner:PERSEPHONE BIOSCIENCES INC

Preparation method for constructing mouse embryo implantation failure model based on fusobacterium variabilis

PendingCN121041324ABacteriaBacteria material medical ingredientsObstetricsFusobacterium varium
The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.
Owner:SHENGJING HOSPITAL OF CHINA MEDICAL UNIVERSITY

Pharmaceutical compositions for treating infant gastrointestinal diseases

Provided herein are pharmaceutical compositions comprising a bacterial population. The bacterial population comprises one bacterial strains or at least two bacterial strains. Such pharmaceutical compositions can be administered to a subject for prevention and / or treatment of dysbiosis and dysbiosis associated conditions and diseases, such as infant gastrointestinal diseases.
Owner:SIOLTA THERAPEUTICS INC

Composition comprising glutamate for caries prevention

PCT designated stageWO2026057840A1Organic active ingredientsCosmetic preparationsOral diseaseRoot caries
Oral composition comprising glutamate, or glutamine, solvate or hydrate thereof, for use in the treatment and / or prevention of caries, wherein the composition is orally administered and increases the pH of the saliva, reducing the risk of caries development. Said oral composition increases the amount of health-associated bacteria and / or decreases the amount of disease-associated bacteria and is useful for the treatment and / or prevention of oral diseases, such as periodontal diseases, halitosis and diseases caused by Candida. Method to determine the response of a mammal to the treatment with glutamate, or with glutamine, solvate or hydrate thereof, comprising determining in saliva the amount of health-associated or disease-associated bacteria or a dysbiosis index, and identifying the mammal as responsive or non-responsive to the treatment.
Owner:FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA

Pediococcus acidilactici P48 capable of relieving constipation and diarrhea and application

The invention belongs to the technical field of biology, and discloses a pediococcus acidilactici strain capable of relieving constipation and diarrhea, the name of the pediococcus acidilactici strain is P48, the classification name of the pediococcus acidilactici strain is pediococcus acidilactici, the preservation number of the pediococcus acidilactici strain is CGMCC No.27885, the preservation date of the pediococcus acidilactici strain is July 13, 2023, and the preservation unit of the pediococcus acidilactici strain is China General Microbiological Culture Collection Center, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici P48 can tolerate the gastrointestinal tract environment, improves the survival rate of the gastrointestinal tract, is beneficial to strain colonization, and can be used for preparing functional microbial agents, food and medicines for relieving constipation or diarrhea; the pediococcus acidilactici P48 disclosed by the invention can be used for carrying out bidirectional regulation on diarrhea and constipation at the same time; meanwhile, intestinal flora imbalance can be improved, immune system activation is promoted, inflammatory factor release is inhibited, and the gastrointestinal tract function is improved.
Owner:TIANJIN DEXINSHENG TECHNOLOGY DEVELOPMENT CO LTD

Method for identifying and isolating keystone bacteria in an ecosystem

ActiveFR3163383B1BiotechnologyMicrobiology
The present invention relates to a method for isolating and identifying a keystone microorganism in an ecosystem of interest. This keystone microorganism carries at least one metabolic function involved in an altered metabolic pathway in a representative sample of the ecosystem. This altered metabolic pathway is then responsible for dysbiosis.
Owner:STARFISH BIOSCIENCE

Bacterial compositions and methods for growing bacteria on particles

The present invention is directed, inter alia, to compositions comprising a population of at least one strain of bacteria at least partially attached to particles, the particles comprise (i) a polysaccharide-based material; and (ii) a metal carbonate. Uses of the compositions, e.g., for prevention or treatment of dysbiosis, and methods for the preparation thereof are further provided herein.
Owner:MYBIOTICS PHARMA LTD

Marinobacterium phage and application thereof

ActiveCN120738130BBiocideAntibacterial agentsMycobacteriophageDisinfectant
The present application belongs to the technical field of microbial prevention and treatment, and particularly relates to a mycobacterium phage and application thereof. Specifically, the present application successfully screens a mycobacterium phage MP1 capable of precisely targeting and killing mycobacterium marinum, which can precisely target and kill specific mycobacterium marinum without causing adverse effects on normal flora. This feature enables the phage therapy to avoid the adverse reactions and flora imbalance problems caused by antibiotic treatment when treating drug-resistant mycobacterium marinum. Meanwhile, the above-mentioned mycobacterium phage MP1 is obtained from nature and is easy to be industrialized, and a drug or environmental disinfectant prepared from the above-mentioned phage not only can reduce the cost, but also has the advantages of green environmental protection and the like, and therefore has good practical application value.
Owner:SHANDONG INST OF DERMATOLOGY & VENEREAL DISEASE CONTROL

Compositions for the prevention and treatment of dysbiosis

The present invention relates to a composition for use in the prevention and / or treatment of dysbiosis. It also relates to the use of said composition for the preparation of a medicament for the prevention and / or treatment of dysbiosis. Furthermore, it relates to a method of preventing and / or treating dysbiosis wherein said composition is administered to a subject in need thereof.SOLUTION: A composition for use in the treatment and / or prevention of signs and / or symptoms associated with atopic dermatitis dysbiosis, xeroderma dysbiosis or oral aphthous dysbiosis, the composition comprising an olive product, trimethylglycine and xylitol, the composition comprising between 0.05% and 4.1% by weight of the olive product; A composition, wherein the olive product is olive oil and / or olive fruit extract; for use for the treatment of dysgeusia (taste disturbance or taste loss) associated with mucosal dysbiosis and / or pulmonary dysbiosis, or for the prevention of dehydration, dry cough and / or cold associated with dysbiosis, wherein the composition comprises an olive product, trimethylglycine and xylitol, wherein the composition comprises between 0.05% and 4.1% by weight of the olive product, and wherein the olive product is olive oil and / or olive fruit extract.SELECTED DRAWING: None
Owner:MUCOSA INNOVATIONS SL

Postbiotic compositions and methods of preparation and use

Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and / or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.
Owner:POSTBIOTICS PLUS RESEARCH LLC

Composition and method for modulating microbiomes with postbiotic ferments

A microbiome modulating composition and a method for producing the microbiome modulating composition are described herein. The method comprises preparing a culture from at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, passaging the culture on a glycogen carbon source to form a postbiotic ferment of the at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, and adding the postbiotic ferment to a carrier. Further disclosed is a method for treating microbial dysbiosis of an urogenital area or a skin area of a user, the method comprising applying the microbiome modulating composition to an urogenital or a skin area of a user. The disclosed methods and microbiome modulating compositions help promote the growth of healthy Lactobacillus spp. bacteria to prevent dysbiosis and other related conditions and infections.
Owner:KIMBERLY CLARK WORLDWIDE INC